{"id":"NCT00235872","sponsor":"Abbott","briefTitle":"Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","officialTitle":"Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2006-07","completion":null,"firstPosted":"2005-10-12","resultsPosted":"2010-01-13","lastUpdate":"2011-04-11"},"enrollment":309,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Adalimumab 40 mg every other week (eow)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the long-term safety and tolerability of repeated administration of adalimumab in Japanese subjects with rheumatoid arthritis.","primaryOutcome":{"measure":"Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement Consisting of 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)","timeFrame":"Every 4 weeks up to Week 24 and every 12 weeks thereafter until Study completion or discontinuation (final value)","effectByArm":[{"arm":"Adalimumab 40 mg Eow","deltaMin":104,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":111,"n":309},"commonTop":["Nasopharyngitis","Adverse drug reaction","DNA antibody positive","Constipation","Insomnia"]}}